PONTE
VEDRA, Fla., Aug. 28,
2023 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., (Nasdaq: CVKD) a biopharmaceutical company developing
tecarfarin, a late-stage novel oral and reversible anticoagulant
(blood thinner) to prevent heart attacks, strokes and deaths due to
blood clots in patients with certain rare medical conditions, today
announced that its Founder, Chairman, and CEO Quang Pham; CFO Matthew
Szot; and CMO, Dr. Douglas
Losordo, will be participating in the H.C. Wainwright 25th
Annual Global Investment Conference, being held virtually and in
person on September 11-13, 2023, at
Lotte New York Palace Hotel in New York City.
The team will hold 1x1 meetings throughout the day on
September 12th and
13th, and the Company's virtual presentation will be
available starting on September
11th at 7:00 a.m.
ET. Please click here to register and view the on-demand
presentation which will be available for 90 days.
To request a meeting with the Cadrenal management team, please
contact your respective H.C. Wainwright representative or email the
Company's investor relations team at CVKD@lythampartners.com.
ABOUT CADRENAL THERAPEUTICS,
INC.
Cadrenal Therapeutics is developing tecarfarin, a late-stage
novel oral and reversible anticoagulant (blood thinner), to prevent
heart attacks, strokes, and deaths due to blood clots in patients
with certain rare medical conditions. Tecarfarin has orphan
drug and Fast Track designations for the prevention of systemic
thromboembolism (blood clots) of cardiac origin in patients with
end-stage renal disease, and atrial fibrillation. Tecarfarin is
specifically designed to leverage a different metabolism pathway
than the oldest and most commonly prescribed Vitamin K antagonist
(warfarin) used in the prevention of thrombosis. Tecarfarin has
been evaluated in eleven (11) human clinical trials and more than
1,000 individuals. In Phase 1, Phase 2, and Phase 2/3 clinical
trials, tecarfarin has generally been well-tolerated in both
healthy adult subjects and patients with chronic kidney disease.
For more information, please visit: www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700,
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-the-hc-wainwright-25th-annual-global-investment-conference-301911433.html
SOURCE Cadrenal Therapeutics, Inc.